Abstract
The global fight against HIV/AIDS is hindered by a lack of drugs in the developing world. When patients in these countries initiate treatment, they typically remain on it until death; thus, policy makers and physicians follow nonabandonment policies. However, treated patients develop resistance to treatment, so in many cases untreated patients might benefit more from the drugs. In this paper we quantify the opportunity cost associated with restricting attention to nonabandonment policies. For this, we use an approximate dynamic programming framework to bound the benefit from allowing premature treatment termination. Our results indicate that in sub-Saharan Africa, the price associated with restricting attention to nonabandonment policies lies between 4.4% and 8.1% of the total treatment benefit. We also derive superior treatment allocation policies, which shed light on the role behavior and health progression play in prioritizing treatment initiation and termination.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
